Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

High-dose cytarabine benefits patients with acute myeloid leukemia and RAS mutations

Nature Clinical Practice Oncology volume 6, pages 3–4 (2009)Cite this article

Neubauer A et al. (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26: 4603–4609

RAS mutations occur in 12–27% of patients with primary acute myeloid leukemia (AML) and in vitro data suggest that these mutations sensitize leukemic cells to cytarabine. Neubauer et al. assessed the role of RAS mutations in response to cytarabine in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Rights and permissions

Reprints and permissions

About this article

Cite this article

High-dose cytarabine benefits patients with acute myeloid leukemia and RAS mutations. Nat Rev Clin Oncol 6, 3–4 (2009). https://doi.org/10.1038/ncponc1268

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1268

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing